For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, ...
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...
Dividend yield and robust drug pipeline are bullish going forward. AbbVie (NYSE:ABBV) shares are plummeting as the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback